Session 3 in the ICER Colloquium Series entitled "Pricing in a Pandemic: Options, Debate, a Path Forward | Monetary Prizes, Compulsory Licensing, Advanced Market Commitments" will be held Friday, April 7, 12-1:30pm ET. This free, interactive on-camera webinar will cover monetary prizes, compulsory […]
Trump’s “Buy American” Executive Order Could Raise Drug Prices
Tensions escalate with pharma as President Trump signs an executive order (EO) today directing the federal government to buy certain drugs and supplies solely from American factories. This action could cause an enormous shake-up of the drug industry, with some industry followers suggesting that up […]
An OM1 Webinar: Exploring Best Practices and Innovation in the New Registry Handbook – 2 Part Series
First published in 2007, the AHRQ publication "Registries for Evaluating Patient Outcomes: A User's Guide" is among the most cited texts on the subject of patient registries. This well-respected reference handbook provides practical information on the design, operation, and analysis of patient […]
What is the Global Access Impact of COVID-19? DRG and Context Matters Weighs In
Mike Ward, Global Head of Thought Leadership at Decision Resources Group talks with Steve Edgar of DRG Global Market Access and Judith Rubinstein, Senior Director of Market Access Data with Context Matters, a Decision Resources Group company. In this video conversation, hear insights about how […]
Virtual ISPOR-FDA Summit 2020 Program Announced | September 29
Virtual ISPOR-FDA Summit 2020, jointly sponsored by ISPOR and the US Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH), has been redesigned to a full virtual event scheduled for September 29. The Summit will provide a forum to engage a variety of healthcare […]
Flatiron Health Collaborates with NICE on RWE for CEA
Flatiron Health, a healthcare technology company focused on cancer research and part of Roche, partnered with NICE to explore how real-world evidence (RWE) can inform the clinical and cost-effectiveness of health technologies. Together, Flatiron Health and NICE will conduct research using data from […]
CMS Issues Lowest Part D Premium Since 2013: AHIP Warns Rebate Rule Could Impact This
CMS has announced the average basic Part D premium for 2021 will be $30.50. This presents a slight uptick from the 2020 average basic Part D premium when premiums were around $30. Premium savings over the past three years have amounted to $1.9 billion, according to CMS, and savings are due to […]
Podcast: Will Patients See Lower Rx Prices, from Trump’s Executive Order?
The latest Patients Rising Podcast features Terry and Bob discussing policies such as co-pay accumulators and rebates, while Katy Talento (former lead health advisor to President Trump) breaks down how the recent Executive Orders to lower prescription drug prices will actually impact patients. Hear […]
The Cost Argument: Requiring Masks for COVID-19
Patients Rising, a national nonprofit organization dedicated to providing support and education to people with chronic and life-threatening illnesses, summarizes the "wear a mask" debate in the United States. A natural study out of the University of Iowa evidenced that the implementation of mask […]
New Value & Outcomes Spotlight Editors Take the Helm
New Editors-in-Chief were recently appointed for Value & Outcomes Spotlight. Zeba M. Khan, RPh, PhD and Laura T. Pizzi, PharmD, MPH will steer the editorial direction of the publication and develop engaging content that will resonate with both HEOR expert and nonexpert audiences around the […]
ISPOR Europe 2020 Is Now Virtual | 14-18 November
Virtual ISPOR Europe 2020, “Improving Health: Establishing Incentives and Sharing Value,” will now be held as a completely virtual conference. Content for Virtual ISPOR Europe 2020 will be delivered both synchronously and asynchronously, through live and on-demand sessions released leading up to the […]
ISPOR’s CSO Dr. Lucinda Orsini shares views on use of RWE by regulators and HTAs
In this interview with Lucinda Orsini, D.P.M., M.P.H., the Associate Chief Science Officer for the Professional Society for Health Economics and Outcomes Research (ISPOR), she shares her views on navigating the opportunities and challenges of working with RWE. Dr. Orsini sees substantial […]
Aetion analyzes RWE impact in 4 recent FDA decisions in infectious disease
Senior Directors from Aetion (Purpura and Harvey) analyzed four approvals for products intended to treat or prevent infectious diseases from 2019 that included RWE studies to highlight how foreign postmarketing data improves understanding of a product’s risk-benefit profile. The products examined […]
A Digital Bridge To Real-Time COVID-19 Data
Several years ago, the Digital Bridge collaborative was formed, consisting of representatives from three key stakeholder communities: public health, the health care delivery system, and electronic health record (EHR) vendors. They concluded that the ubiquitous footprint of electronic health records […]
AMCP Introduces AMCP Collaborate online community to engage in discussions of managed care
AMCP, the organization for managed care pharmacists, today introduced AMCP Collaborate, an online community designed to give members a new platform to engage with each other in discussions impacting managed care pharmacy. AMCP Collaborate will have private communities for the following groups: […]
5 Questions for the New Chair of NICE Sharmila Nebhrajani
S. Nebharajani assumed the role of chair of NICE in May 2020, most recently serving as CEO of Wilton Park, leading the Global Health program looking at issues of AI and data for health systems in Africa, Asia, among other responsibilities. Medscape UK sat down for an interview, exploring […]
Former FDA Commish Califf: Weighing the Benefits & Risks of the Growing Number of Observational Treatment Assessments
In a recently published JAMA Viewpoint, former FDA Commissioner Robert Califf and colleagues mused about a growing concern about inferring causation about benefits and risks of potential therapeutics for COVID-19 derived from nonrandomized studies. The authors mused, " whether these reports just […]
New Report: Provider Perceptions of Value-Based Care
Provider Perceptions of Value-Based Care aimed to understand provider views on value-based care and their partnership with private and public payers to implement these models. Highlights from the 21-page report, released April 2020 from Xtelligent Healthcare Media, include Provider […]
Trump v. Pharma: a “Kinda Sorta” War
Politico summarizes Trump's "kinda sorta" war with pharma, kicked off last week with presidential tweets about "nasty" drug ads that "lied" about the impact of his pricing executive orders on senior's drug premiums and the price of prescription drugs. It's unclear exactly which drug ads he was […]
Unsupported Price Hikes: Drug manufacturers will be penalized in NASHP’s new model bill
The National Academy for State Health Policy’s (NASHP) newly introduced model law, an Act to Protect Consumers from Unsupported Price Increases on Prescription Drugs, charges substantial fines on pharmaceutical manufacturers that impose unjustified price increases and then uses the fines’ revenues […]
Medicare turns 55, and now’s the time to look at Part D – did it work?
On July 30, 1965, President Lyndon B. Johnson signed into law legislation that established the Medicare and Medicaid programs. The Part D prescription drug benefit was implemented in 2006, providing affordable prescription drug coverage to seniors and individuals living with disabilities. You […]
New Data Released: Higher cost-sharing for brand medicines experienced by commercially insured patients
Health plans are increasingly using deductibles and coinsurance to shift more of the cost of care to chronically ill patients who take brand name pharmaceuticals. Despite rebates that are negotiated with pharma to reduce brand medicine prices, most patients who have deductibles and copays do not […]
Payers probably won’t pass COVID savings onto members, despite pandemic-driven boon
Payers were prepared for skyrocketing medical costs due to COVID, but the opposite happened: people consumed less healthcare, on average. This resulted in large savings for health plans. Will consumers see lower premiums next year? Numerous insurers across the country have announced plans to hike […]
Not interested: Pharma execs refuse White House meeting over drug pricing executive orders
Trump's recent executive orders linking drug prices in Medicare to lower prices abroad caused a significant rift with the pharma industry executives. Executives declined to attend a White House meeting scheduled for Tuesday, July 28 on drug prices, according to media reports. Industry argues such […]
High-Value Care Every Time: Recommendations From The National Quality Task Force
To address the high-cost, low-value healthcare dilemma in the United States, the National Quality Forum (NQF) launched the National Quality Task Force in 2019. The Task Force sought to address systemic limitations and define actionable opportunities to improve delivery system alignment, so that […]
Cytel Scientists Call for a “Statistician-First Workflow” to Optimize Drug Development
Adaptive trial designs within oncology are described by Cytel scientists, and address data, statistical, and commercial and scientific value of flexible adaptive designs. A "Holistic Approach" to program development is delineated, wherein development plans are not created study by study, but across […]
Incorporating Value-based Care Into Oncology
Value-based care within insurance design utilizes evidence-based medicine to distinguish high-value and low-value diagnostics and treatments. The goals of value-based care are to shift spending and coverage toward high-value care and reduce the use of low-value practices. Within oncology, several […]
Viewpoint in JAMA: Integrating Personalized Medicine with Population Health Management: The Path Forward
In this viewpoint article published in the Journal of the American Medical Association, the authors posit that genome-wide DNA sequencing will likely become a part of regular medical practice and represents an era of ‘personalized medicine’. Costs associated with genomic screening will be […]
A Military-Civilian Perspective on Real-World Evidence to Support Regulatory Decision Making
This article summarizes how the US Military Health System (MHS) used real-world data (RWD) during the Iraq and Afghanistan Wars to achieve historic rates of survival and describe a new era of collaboration between the US Department of Defense (DoD) and the US Food and Drug Administration (FDA). The […]
New Report: Provider Perceptions of Value-Based Care
Provider Perceptions of Value-Based Care aimed to understand provider views on value-based care and their partnership with private and public payers to implement these models. Highlights from the 21-page report, released April 2020 from Xtelligent Healthcare Media, include Provider […]
